Werewolf Therapeutics (HOWL) FCF Margin (2022 - 2026)

Werewolf Therapeutics (HOWL) has reported FCF Margin for 4 consecutive years, with 31.57% the latest figure, recorded in Q2 2026.

• On a quarterly basis, FCF Margin changed N/A year-over-year to 31.57% in Q2 2026; TTM through Jun 2026 was 143.56%, a 40620310.0% increase from a year earlier, with the FY2024 full-year figure at 2970.63%, down 280325.0% from the prior year.
• FCF Margin was 31.57% for Q2 2026 at Werewolf Therapeutics, up from 95833.33% in the prior quarter.
• Over five years, FCF Margin peaked at 31.57% in Q2 2026 and troughed at 95833.33% in Q4 2024.
• A 4-year average of 9129.87% and a median of 225.49% in 2023 frame the typical range for FCF Margin.
• Across the five-year window, FCF Margin jumped 18959 bps in 2023 and plunged 9551468 bps in 2024, its largest moves.
• Over 4 years, FCF Margin stood at 170.09% in 2022, then slumped by 87 bps to 318.65% in 2023, then slumped by 29974 bps to 95833.33% in 2024, then jumped by 100 bps to 31.57% in 2026.
• The last three FCF Margin figures came in at 31.57% (Q2 2026), 95833.33% (Q4 2024), and 1241.82% (Q2 2024), per Business Quant data.